<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127917</url>
  </required_header>
  <id_info>
    <org_study_id>15BGIA22710012</org_study_id>
    <nct_id>NCT03127917</nct_id>
  </id_info>
  <brief_title>Effect of L-Citrulline on Vascular Function</brief_title>
  <official_title>Impact of Reduced Arterial Stiffness on Peripheral Vascular Function and Mobility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas Tech University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this project is to determine the importance of peripheral vascular function
      on gait performance in older adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project employed a placebo controlled, double-blind, crossover trial. Participants were
      randomized to oral L-citrulline (6 g/day) or placebo (maltodextrin) for 14 days, and switched
      to the other treatment for another 14 days after washout. Peripheral vascular function was
      assessed under conditions of rest, leg exercise, and cognitive engagement. Gait performance
      was assessed using clinical walking tests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">March 22, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind research study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Flow</measure>
    <time_frame>baseline and 2 weeks for L-citrulline and placebo</time_frame>
    <description>Femoral blood flow during leg exercise and carotid blood flow during mental activity measured using Doppler ultrasound. Blood-oxygen-level dependent contrast imaging of the brain using functional magnetic resonance imaging (fMRI) during cognitive functioning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gait Performance</measure>
    <time_frame>baseline and 2 weeks for L-citrulline and placebo</time_frame>
    <description>Usual and fast walking speeds measured during short (7m) and long (400m) distances.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Citrulline</condition>
  <condition>Blood Flow</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>CitrullinePlacebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects allocated to the CitrullinePlacebo study arm received L-citrulline first, followed by placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PlaceboCitrulline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects allocated to the PlaceboCitrulline study arm received placebo first, followed by L-citrulline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-citrulline</intervention_name>
    <description>L-citrulline capsules given at 6 g/day</description>
    <arm_group_label>CitrullinePlacebo</arm_group_label>
    <arm_group_label>PlaceboCitrulline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin capsules given as placebo</description>
    <arm_group_label>CitrullinePlacebo</arm_group_label>
    <arm_group_label>PlaceboCitrulline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  older adults

          -  women and men

          -  aged 60-79 yrs

          -  must be able to swallow capsules

          -  fully mobile without assistive walking devices

        Exclusion Criteria:

          -  have physician diagnosed cardiovascular, pulmonary, or metabolic disease

          -  are current smokers

          -  currently taking medications affecting cardiovascular function

          -  have high blood pressure (&gt;159/99 mmHG)

          -  have high fasting blood glucose (&gt;110 mg/dL)

          -  are considered obese (body mass index â‰¥ 30 kg/m2)

          -  have orthopaedic limitations that limit walking ability

          -  have pacemaker or other metal objects in their body
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Tech University</investigator_affiliation>
    <investigator_full_name>Joaquin U Gonzales, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Gait Speed</keyword>
  <keyword>Cognitive Function</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Raw data for outcome variables will be made available on the online general repository &quot;figshare&quot; within 12 months of funding end date.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

